In addition, this study sought to characterize the phenotypic expression of early AD in carriers of APOE4 and BCHE-K relative to other genotype groups with respect to accumulations of amyloid and tau pathology, neurodegeneration, glial activation, hippocampal atrophy, ventricular expansion, and cognitive function. This evidence concerns the gene MAPT and Alzheimer disease.